BMS Bet $800M on a Chinese Cancer Drug. It Just Paid Off.
Bristol Myers Squibb paid $800 million for a cancer drug from a Chinese biotech nobody was watching. It just hit both survival endpoints in the toughest form of breast cancer, marking the first time a bispecific ADC has pulled off that feat. The $8.4 billion bet is starting to look like a bargain.
In 2023, Bristol Myers Squibb wrote an $800 million check to a Chinese biotech most people had never heard of. The bet: a new type of cancer drug that hadn't yet proven itself in a late-stage trial. Wall Street raised eyebrows. Skeptics questioned whether BMS was overpaying for unproven science from a relatively unknown partner.
This week, the skeptics got quiet.
The Drug That Just Made History
Izalontamab brengitecan (mercifully nicknamed "iza-bren") just hit both of its primary goals in a Phase 3 trial for one of the hardest-to-treat cancers in existence: triple-negative breast cancer, or TNBC.
TNBC is the villain nobody wants to face. It accounts for roughly 10-15% of all breast cancers, but it's disproportionately deadly. Unlike other breast cancers, TNBC lacks the three most common molecular targets that drugs typically latch onto. Think of it like trying to pick a lock with no keyhole. Standard chemotherapy has been the go-to, but outcomes remain grim: five-year survival for metastatic TNBC sits at just 15%.
That's what makes this readout so significant. In a 418-patient trial called BL-B01D1-307, iza-bren showed statistically significant improvements in both progression-free survival (how long until the cancer grows back) and overall survival (how long patients live) compared to standard chemotherapy. Those are the two measurements oncologists care about most, and hitting both in the same trial is rare.
Even rarer? This is the first bispecific ADC ever to pull off that dual win in TNBC.
Wait, What's a Bispecific ADC?
Let's unpack that, because it matters.
An antibody-drug conjugate, or ADC, is basically a guided missile for cancer. You take an antibody (which finds the tumor) and attach a toxic payload (which kills it). The antibody delivers the poison directly to cancer cells, sparing healthy tissue. It's one of the hottest drug classes in oncology right now.
Most ADCs target a single protein on the surface of cancer cells. Iza-bren targets two: EGFR and HER3. These are proteins that TNBC cells often overexpress, like a neon sign on the tumor's surface. By locking onto both signals simultaneously, the drug has two chances to find and destroy its target instead of one. Think of it as a heat-seeking missile with two sensors instead of one.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That dual-targeting approach is what makes iza-bren "bispecific," and it's what caught BMS's attention back in 2023.
The $8.4 Billion Handshake
The company behind iza-bren is SystImmune, a subsidiary of China's Sichuan Biokin Pharmaceutical. Not exactly a household name in Western pharma circles. But BMS saw something in their science and structured a deal that could ultimately be worth $8.4 billion in total, including development and commercial milestones.
The terms tell you a lot about how confident BMS was. They paid $800 million upfront (not pocket change, even for Big Pharma) and secured exclusive rights to develop and sell iza-bren outside mainland China and the United States, while the two companies co-develop and co-commercialize the drug in the U.S. SystImmune kept mainland China rights. BMS pays tiered royalties on sales in markets outside the U.S. and mainland China.
For BMS, this wasn't just a one-off licensing deal. It was their entrance ticket into the ADC space, a category where competitors like Gilead (with Trodelvy) and AstraZeneca/Daiichi Sankyo (with Enhertu) have already built multi-billion-dollar franchises.
Three Phase 3 Wins and Counting
The TNBC readout is impressive on its own. But context makes it even more compelling: this is iza-bren's third Phase 3 victory. The drug previously hit its primary endpoint in a trial for nasopharyngeal cancer conducted in China. Regulatory applications for nasopharyngeal cancer and esophageal cancer have already been submitted to China's National Medical Products Administration.
The FDA has also taken notice, granting iza-bren a breakthrough therapy designation for previously treated non-small cell lung cancer with EGFR mutations. In China, the drug holds breakthrough designations across seven different cancer types.
That breadth is unusual for a single drug. Most ADCs carve out a niche in one or two tumor types. Iza-bren is shaping up to be a platform asset, the kind of drug that could generate revenue across a wide portfolio of solid tumors. If you're BMS, that $800 million upfront is starting to look like a bargain.
The Asterisk: Where's the Full Data?
Before we pop the champagne, a couple of important caveats.
First, BMS hasn't released the actual numbers yet. We know the trial hit its endpoints at a prespecified interim analysis. We know the improvements were "statistically significant and clinically meaningful." But we don't know the specific hazard ratios, median survival times, or safety details. Those are being saved for an upcoming medical meeting, which is standard practice but still leaves investors guessing about the magnitude of the benefit.
Second, this trial was conducted entirely in China by SystImmune's parent company. That's not inherently a problem; the science doesn't change based on geography. But the FDA will likely want to see confirmatory data from a more globally diverse patient population before granting approval in the U.S. BMS is running its own Phase 2/3 trial of iza-bren in first-line TNBC patients.
So while this is a huge validation of the drug's potential, the road to U.S. revenue still has a few more miles on it.
Where Iza-Bren Fits in a Crowded Battlefield
TNBC treatment has been evolving fast. Gilead's Trodelvy (sacituzumab govitecan), a TROP-2-targeting ADC, recently muscled its way into first-line TNBC treatment guidelines. The NCCN now lists it as a preferred option for certain PD-L1-negative patients, and a combination of Trodelvy plus Merck's Keytruda showed nearly 60% response rates in PD-L1-positive TNBC.
That's the competitive landscape iza-bren is walking into. But there's a key difference in how the drugs work. Trodelvy targets TROP-2; iza-bren targets EGFR and HER3. Different keyholes, different keys. In theory, this means they could serve different (or overlapping) patient populations, and some patients who don't respond to one mechanism might benefit from the other.
The bigger question for BMS is whether iza-bren can carve out a meaningful share in a market that's getting more crowded by the quarter. Merck and Daiichi Sankyo are developing their own HER3-targeting ADC. BioNTech has an EGFR/HER3 candidate in its pipeline. The ADC gold rush is very much on.
Why This Matters Beyond One Drug
Zoom out, and this story is about more than iza-bren. It's about the tectonic shift happening in global drug development.
Chinese biotech companies accounted for 28% of large pharma's licensing deals in 2024, totaling $41.5 billion in deal value. By early 2025, Chinese firms represented 32% of global biotech licensing value. The flow of innovative science from China to Western pharma companies has gone from a trickle to a firehose, with oncology (and ADCs in particular) leading the way.
BMS's SystImmune deal was one of the earlier, bolder bets in this wave. The positive Phase 3 data validates not just the drug but the entire strategy of looking east for innovation. Expect more mega-deals like this one as other Big Pharma companies race to secure the next breakthrough from China's biotech ecosystem.
The Bottom Line
Bristol Myers Squibb bet big on an unproven ADC from a Chinese partner nobody was watching. Three Phase 3 wins later, that bet is looking increasingly smart. Iza-bren's dual-target design, its breadth across multiple tumor types, and its strong survival data in the toughest form of breast cancer all point to a potentially massive commercial opportunity.
The full data will tell us how good this drug really is. But the direction is clear. And for metastatic TNBC patients facing limited treatment options, a new option can't come soon enough.
Analysts currently rate BMS a moderate buy. If iza-bren's complete dataset matches the headline results, don't be surprised if that rating moves higher. Sometimes the best deals are the ones that make everyone nervous at first.
Funding & Financings4 min read
The $130M Bet That CGRP Isn't the Only Way to Fight Migraines
A brand-new biotech just launched with $130 million to target migraines through a completely different pathway than every existing preventive drug. For patients who don't respond to CGRP therapies, Slate Medicines might be building the backup plan they've been waiting for.
